June 10, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Insmed Incorporated (NASDAQ:INSM) shares over potential securities laws violations by Insmed and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Insmed Incorporated (NASDAQ:INSM) concerning whether a series of statements by Insmed regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On June 8, 2016, post-market, Insmed Incorporated announced that it had withdrawn a European marketing application submitted to the European Medicines Agency for its lung disease drug Arikayce. Insmed Incorporated stated that the marketing application was based on data from a mid-stage clinical study that didn't support enough evidence for an approval from the European Medicines Agency. Insmed Incorporated stated that the Company will resubmit the application when data is available from a later study.
Shares of Insmed Incorporated (NASDAQ:INSM) declined to $9.95 per share on June 9, 2016.

On June 10, 2016, NASDAQ:INSM shares closed at $10.88 per share.